Kleine-Levin Syndrome

Overview

Kleine-Levin syndrome (KLS) is a rare, relapsing-remitting neurological sleep disorder. During episodes, people may sleep for most of the day and experience confusion, slowed thinking, apathy, altered perception, disinhibition, changes in eating, or—in some patients—hypersexuality; they usually return to their usual alertness and functioning between episodes. It most often begins in adolescence and is reported more often in males, although it can affect people of any sex and age. Episodes commonly last days to weeks, and the condition often attenuates or remits over time, but its course is highly variable and can be profoundly disruptive to education, work, relationships, and safety. Lithium systematic review

There is no proven cure or disease-modifying treatment. Current care is principally supportive during episodes—supervision, protection from driving and other hazards, accommodations for school or work, and attention to hydration, nutrition, mood, and behavior—plus individualized attempts to reduce episode burden. The American Academy of Sleep Medicine (AASM) conditionally suggests lithium for adults with KLS; stimulants and other medicines may be used for selected symptoms, but they do not reliably treat the full syndrome. AASM clinical practice guideline

Scope of Recent Research (2020–present)

From 2020 through October 20, 2026, KLS research has been active but small relative to more common sleep disorders. The dominant questions are what causes the episodic brain-state change, whether genetic susceptibility interacts with early-life or immune-related factors, and whether measurable biomarkers can improve diagnosis and identify treatment-responsive subgroups. The field has produced promising genetic, protein-biomarker, circadian, imaging, and medication-repurposing leads, but it is not close to a curative therapy because the underlying causal mechanism remains unconfirmed and therapeutic evidence is still mostly observational or case-based. An update on KLS Lithium systematic review

Major Breakthroughs and Emerging Therapies

Lithium and other repurposed medicines. Lithium remains the most studied preventive medicine, not a cure. A 2026 systematic review found that published reports often describe fewer, shorter, or less severe episodes during lithium exposure, but judged the evidence to be predominantly case-based and of very low certainty. The largest available non-randomized, open-label comparison reported fewer episodes and fewer incapacitated days among lithium-treated patients, yet its design cannot establish that lithium caused the benefit; KLS can also improve naturally over time. Lithium requires laboratory monitoring because of potential thyroid, kidney, gastrointestinal, and neurologic adverse effects. Lithium systematic review AASM clinical practice guideline

Circadian-targeted treatment. A 2024 case series reported apparent resolution of hypersomnia episodes in two patients after starting ramelteon, a prescription medicine that activates melatonin receptors and can strengthen timing signals for sleep and circadian rhythms. One patient remained free of further episodes for more than one year and the other for approximately two years except after missed or substantially delayed doses. These observations are encouraging but cannot distinguish a drug effect from the fluctuating natural history of KLS, concurrent treatments, or spontaneous remission; controlled or carefully designed individual (“N-of-1”) trials are needed. Ramelteon case series

Genetics and precision-medicine foundations. A worldwide 2021 genome-wide association study of 673 KLS cases identified an association near the TRANK1 locus, found enrichment of circadian-regulation pathways, and reported that the association was strongest in a subgroup reporting birth difficulties. These findings do not provide a gene-therapy target or diagnostic genetic test, but they support the idea that KLS may arise from multiple inherited risk factors interacting with developmental or environmental exposures. TRANK1 genome-wide association study

Biomarker-led and neuroimmune research. A 2022 study used high-throughput proteomics—measurement of many proteins at once—in cerebrospinal fluid and blood. It found protein patterns consistent with altered microglial/immune signaling and blood-brain-barrier biology, and its exploratory machine-learning classifiers separated KLS cases from controls in independent validation samples. This is an important diagnostic and mechanism-discovery advance, but the protein signatures require validation in larger and more diverse cohorts before they can guide treatment or serve as clinical tests. Proteomic biomarker study

Circadian physiology as a treatment filter. A 2026 actigraphy and melatonin study found broadly preserved endogenous melatonin timing and amplitude in 20 people with KLS during remission and relapse. That result cautions against assuming that KLS is simply a disorder of a shifted biological clock, while not ruling out that selected patients could benefit from therapies such as ramelteon through other circadian or sleep-regulating mechanisms. Circadian melatonin study

Clinical Trials and Experimental Approaches

There are no phase I–III curative drug, gene, cell, or RNA-therapy trials for KLS to report as of October 20, 2026. The main therapeutic signals remain lithium observational studies and individual case reports, including the two-patient ramelteon series; neither provides the randomized evidence required to establish efficacy or cure. Lithium systematic review Ramelteon case series

A notable recently completed KLS-related registered study is NARCOGLIE (NCT03754348), sponsored by University Hospital, Montpellier. This was an interventional, phase-not-applicable PET imaging study using the tracer [18F]DPA-714 to investigate microglial activation in people with narcolepsy type 1 and KLS; it enrolled 78 participants and completed in November 2021. It was a mechanistic imaging study rather than a treatment trial, and no results were posted in the registry. NARCOGLIE trial record

Methodologies and Scientific Approaches

Researchers are combining international case collections with genome-wide association analysis to search for inherited susceptibility, while interpreting results cautiously because KLS is rare and genetically complex. The TRANK1 study illustrates this approach: it compared hundreds of affected individuals with thousands of controls and then examined biological pathways and reported birth-related exposures. TRANK1 genome-wide association study

Other teams are studying the disorder closer to the time of symptoms through blood and cerebrospinal-fluid protein profiling, machine-learning classifiers, PET imaging of possible neuroinflammation, wrist actigraphy, and melatonin sampling. Together, these platforms aim to produce biomarkers that can distinguish KLS from psychiatric and other hypersomnia disorders, reveal whether immune or brain-circuit changes occur during episodes, and eventually match patients to targeted treatments. Proteomic biomarker study NARCOGLIE trial record Circadian melatonin study

Leading Institutions and Funding

Stanford University’s Center for Sleep Sciences and Medicine, Assistance Publique–Hôpitaux de Paris and the Pitié-Salpêtrière National Reference Center in France, University Hospital Montpellier, Washington University School of Medicine, and collaborating sleep centers in Europe and Asia are prominent contributors to recent KLS research. Stanford- and Paris-linked investigators led the large TRANK1 genetic study and the international proteomics work; Washington University and Stanford investigators collaborated on the ramelteon case series. TRANK1 genome-wide association study Proteomic biomarker study Ramelteon case series

Funding is limited and collaborative. The 2022 proteomics study reported U.S. National Institutes of Health support, including grant identifiers R01MH080957, T32HL110952, and S10OD023452, alongside non-U.S. support; the Kleine-Levin Syndrome Foundation was also represented among the study’s collaborators. Publicly available reports identify these programs but do not provide a KLS-specific dollar total for the project. Proteomic biomarker study

Strengths, Limitations, and Challenges

The strongest recent progress is in creating plausible, testable biological hypotheses: genetic susceptibility linked to circadian pathways, protein signatures suggestive of altered immune and blood-brain-barrier biology, and imaging approaches directed at neuroinflammation. These advances may make diagnosis faster and enable biologically informed trials rather than relying solely on symptom-based treatment. TRANK1 genome-wide association study Proteomic biomarker study

The central limitation is rarity. Small cohorts, fluctuating symptoms, spontaneous improvement, inconsistent episode definitions, and sparse safety reporting make uncontrolled treatment successes difficult to interpret. Lithium is the best-supported preventive option but is not reliably effective, can cause clinically important adverse effects, and requires monitoring; ramelteon is promising but rests on only two cases. No validated biomarker yet identifies who will respond to a given treatment, and no research has established a target suitable for gene editing, cell therapy, or other curative platforms. Lithium systematic review Ramelteon case series

Outlook and Future Directions

A cure for KLS is not imminent, but the field is moving from descriptive case reports toward measurable biology. The most important milestones to watch are independent validation of blood or cerebrospinal-fluid biomarker panels, publication of the completed PET imaging findings, larger prospective studies of lithium and ramelteon with standardized episode outcomes and safety monitoring, and international natural-history cohorts that can support adaptive or N-of-1 trials. A genuine curative strategy will likely require first showing a reproducible causal mechanism—such as a defined immune, developmental, genetic, or neural-circuit process—and then demonstrating that altering it prevents episodes durably and safely. Proteomic biomarker study NARCOGLIE trial record Lithium systematic review

References

• An update on Kleine-Levin syndrome — Qasrawi and BaHammam, 2023.
• AASM clinical practice guideline — American Academy of Sleep Medicine, 2021.
• Lithium systematic review — Queirós Silva et al., 2026.
• Ramelteon case series — Dominguez et al., 2024.
• TRANK1 genome-wide association study — Ambati et al., 2021.
• Proteomic biomarker study — Hédou et al., 2022.
• Circadian melatonin study — Sleep Medicine, 2026.
• NARCOGLIE trial record — ClinicalTrials.gov, 2024.